Serum Lp-PLA2: as a novel viewpoint in periodontal treatment of hyperlipidaemics.
OBJECTIVE
To evaluate the effects of periodontal treatment on serum lipoprotein-associated phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) levels in hyperlipidaemic patients with periodontitis.


METHODS
The study included 52 hyperlipidaemics and 28 systemically healthy controls (C) with periodontitis. Of the 52 hyperlipidaemics, 29 received a suggested diet (HD), and 23 of them were prescribed statin (HS). Clinical periodontal parameters, serum lipids, Lp-PLA2, and CRP levels were assessed at the baseline and 2 months after the completion of the nonsurgical periodontal treatment (2MPT). Serum parameters were also evaluated 1 week following the periodontal treatment (1WPT).


RESULTS
At the baseline, patients in the HS group had a higher percentage of bleeding on probing than those in the C and HD groups. Hyperlipidaemics had higher serum triglyceride levels than the control group at 2MPT compared to the baseline. At 2MPT, the levels of Lp-PLA2 in the HS group were significantly higher compared to the baseline and 1WPT. There were no statistically significant differences in CRP levels between study periods for all groups.


CONCLUSIONS
The periodontal treatment may affect the inflammatory control of hyperlipidaemic patients with periodontitis via increased Lp-PLA2 levels and severity of the impaired lipid metabolism. These findings may be important regarding the therapeutic strategies for hyperlipidaemics with periodontitis.
Özlem
Ö
Fentoğlu
Fatma Yeşim
FY
Kirzioğlu
Memduha
M
Tözüm Bulut
Şivge
Ş
Kurgan
Havva
H
Koçak
Recep
R
Sütcü
Banu
B
Kale Köroğlu
Meral
M
Günhan
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood*; D000328:Adult; D000704:Analysis of Variance; D002097:C-Reactive Protein; D012534:Dental Scaling; D018752:Diet, Fat-Restricted; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000150:complications* / Q000628:therapy; D000960:Hypolipidemic Agents / Q000097:blood / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010518:Periodontitis / Q000097:blood* / Q000150:complications* / Q000628:therapy
D000960:Hypolipidemic Agents; D002097:C-Reactive Protein; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase